Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Quiz|Articles|May 3, 2026
Dermatology Times Spot Test: May 3, 2026
Author(s)Marie Bosslett, Assistant Editor
Listen
0:00 / 0:00
Key Takeaways
- Weekly quiz-based content is positioned to assess knowledge of essential dermatology topics, evolving trends, and recent breakthroughs.
- This week’s focus is the current evidence base and latest research developments related to acne.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Advertisement
Welcome to Dermatology Times' Spot Test!
Each week, dive into a series of thought-provoking questions designed to test your understanding of essential topics, trends, and breakthroughs in dermatology. This week, we’ll focus on the latest research on
Do you have a set of quiz questions to share? Contact editor Marie Bosslett at
In the cross-sectional study, which skin types were more commonly associated with acne scarring?
What was the approximate lesion clearance rate achieved by the triple therapy regimen of isotretinoin, spironolactone, and diammonium glycyrrhizinate?
Which type of acne scars responded best to fractional CO₂ laser treatment?
Advertisement
Related to this article
Treatment success reached 56.7% and total lesions fell 71.8% with up to 52 weeks of oral denifanstat, with no adverse event-related discontinuations.
Dermatology clinicians at a Case-Based Roundtable in Austin, Texas, discussed real-world strategies for sequencing topical therapy, phototherapy, and ruxolitinib cream across pediatric and adult vitiligo cases.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Two claims analyses of hidradenitis suppurativa showed similar symptom prevalence in males and females and lower dermatologist access among rural patients than urban patients.
Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced cSCC, and screening aesthetic patients.
In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.
Patients with plaque psoriasis treated with roflumilast cream or foam reported greater improvements in sexual function and relationships vs vehicle, including those with genital involvement at baseline.
Advertisement
Advertisement
Trending on Dermatology Times
1
The Value of Precision Medicine in Atopic Dermatitis and Skin Cancers
2
JAK Inhibitor Safety in Atopic Dermatitis: Long-Term Epidemiology Data
3
No Observed Skin Lesion Flares After Switching to Upadacitinib in Atopic Dermatitis
4
Day 2 Recap: Fall Clinical 2026
5